(Q48430556)

11 February 2018

title

Treatment of depression in Parkinson's disease with moclobemide: A pilot open-label study (English)

1 reference

11 February 2018

1 reference

Giménez-Roldán S

1

1 reference

11 February 2018

Dobato JL

series ordinal

2

1 reference

11 February 2018

Mateo D

series ordinal

3

1 reference

11 February 2018

publication date

1 December 1997

1 reference

11 February 2018

number of pages

7

1 reference

Parkinsonism and Related Disorders

inferred from page(s)

published in

1 reference

11 February 2018

volume

3

1 reference

11 February 2018

issue

4

1 reference

11 February 2018

page(s)

219-225

1 reference

11 February 2018

Depression and Parkinson's disease: a review

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

An estimate of the incidence of depression in idiopathic Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Depression in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Neuropsychological impairment in Parkinson's disease with and without depression

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Gastrointestinal symptoms in Parkinson disease: 18-month follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Increase of Parkinson disability after fluoxetine medication

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Localization of distinct monoamine oxidase a and monoamine oxidase b cell populations in human brainstem

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Moclobemide — Placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Molecular neuroanatomy of monoamine oxidases in human brainstem

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Distinct monoamine oxidase A and B populations in primate brain

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Biochemistry and pharmacology of moclobemide, a prototype RIMA

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Parkinsonism: onset, progression, and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

1 reference

7 January 2021

An Inventory for Measuring Depression

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Safety and efficacy during long-term treatment with moclobemide

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Parkinson's disease and depression: psychometric properties of the Beck Depression Inventory

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Moclobemide versus clomipramine in endogenous depression. A double-blind randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Moclobemide versus imipramine in depressed out-patients

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Monoamine oxidases of the human brain and liver

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Dopamine is a monoamine oxidase B substrate in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

The Therapeutic Potential of Moclobemide, a Reversible Selective Monoamine Oxidase A Inhibitor in Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Effects of moclobemide on depressive symptoms and cognitive performance in a geriatric population: a controlled comparative study versus imipramine.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Mechanisms underlying emotional variation in parkinsonian tremor

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Pharmacology of reversible and selective inhibitors of monoamine oxidase type A.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Effects of monoamine oxidase a inhibition on plasma biogenic amine metabolites in depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Depression, intellectual impairment, and Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2897%2900028-X

7 January 2021

10.1016/S1353-8020(97)00028-X

Identifiers

DOI

1 reference

11 February 2018

1 reference

11 February 2018